多发性骨髓瘤中的静脉血栓栓塞症——预防措施的选择、直接口服抗凝药的作用及特殊考量
多发性骨髓瘤患者静脉血栓栓塞症(VTE)风险显著升高,疾病与治疗相关因素共同参与其致栓性,免疫调节药物(IMiDs)和大剂量地塞米松尤甚。本文综述骨髓瘤血栓形成机制、常用化疗方案相关血栓风险、当前风险分层及不同抗凝药用于血栓预防的证据,并提出修订的风险分层,讨论肾功能不全和复发性血栓等疑难患者的管理。
要点
- 骨髓瘤相关VTE风险由疾病与治疗因素共同决定,IMiDs和大剂量地塞米松可增强致栓性。
- 尽管常规使用血栓预防,患者仍可发生VTE及其后遗症,最佳预防药物选择与剂量尚不完全明确。
- 直接口服抗凝药在该领域的应用受到关注,本文提出修订的风险分层并讨论特殊患者管理。
核心结论
- 骨髓瘤患者VTE致栓性由多因素构成,疾病与治疗相关因素均起重要作用。
- 血栓预防药物的最佳选择与剂量尚不完全明确,直接口服抗凝药在该领域的应用受到关注。
- 本文提出修订的风险分层,并讨论肾功能不全和复发性血栓等疑难患者的管理。
研究设计与样本
- 本文为综述,讨论骨髓瘤血栓形成机制、其与常用化疗方案的关系、当前风险分层及不同抗凝药用于血栓预防的证据。
主要发现
- 多发性骨髓瘤与显著升高的VTE风险相关,导致大量疾病负担和死亡。
- 免疫调节药物(IMiDs)和大剂量地塞米松已知可增强骨髓瘤的致栓潜力。
- 尽管常规使用血栓预防,骨髓瘤患者仍可发生VTE及其后遗症。
临床怎么用
- 对需要以IMiD为基础方案治疗的骨髓瘤患者,长期以来主张在开始治疗前评估VTE风险。
- 本文提出修订的风险分层,并考虑肾功能不全和复发性血栓等疑难患者的管理。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Multiple myeloma is associated with a significant risk of venous thromboembolism (VTE), causing substantial levels of morbidity and mortality. The thrombogenicity of myeloma is multifactorial, with disease- and treatment-related factors playing important roles. Immunomodulatory drugs (IMiDs) and high-dose dexamethasone, in particular, are known to enhance the thrombotic potential of myeloma. For this reason, assessment of the VTE risk has long been advocated prior to treatment initiation in patients with myeloma requiring IMiD-based regimens. However, despite routine use of thromboprophylaxis, these patients can still develop VTE and its sequelae. The optimum choice and dose of thromboprophylactic drug is not entirely clear, and with this, there is growing interest regarding use of the direct oral anticoagulants in this setting. In this review we discuss the pathogenesis of thrombosis in multiple myeloma, its relation to some of the commonly used chemotherapeutic regimens, current risk stratification and the evidence supporting the different anticoagulants used as thromboprophylaxis. We propose an amended risk stratification, and consider management of challenging patients, including those with renal impairment and recurrent thrombosis.
引用
- Swan D, Rocci A, Bradbury C, et al. Venous thromboembolism in multiple myeloma - choice of prophylaxis, role of direct oral anticoagulants and special considerations. Br J Haematol. 2018. PMID: 30450656. doi:10.1111/bjh.15684
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。